BioAtla, Inc. Share Price
BCABBioAtla, Inc. Stock Performance
Open $0.20 | Prev. Close $0.19 | Circuit Range N/A |
Day Range $0.20 - $0.21 | Year Range $0.15 - $1.42 | Volume 12,149 |
Average Traded $0.20 |
BioAtla, Inc. Share Price Chart
About BioAtla, Inc.
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
BioAtla, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
04-Feb-26 | $0.19 | $0.21 | +7.81% |
03-Feb-26 | $0.17 | $0.19 | +14.97% |
02-Feb-26 | $0.25 | $0.17 | -37.69% |
30-Jan-26 | $0.30 | $0.27 | -4.96% |
29-Jan-26 | $0.30 | $0.28 | -8.74% |
28-Jan-26 | $0.32 | $0.31 | -3.44% |
27-Jan-26 | $0.33 | $0.32 | -7.78% |
FAQs on BioAtla, Inc. Share Price
Can I buy BioAtla, Inc. shares in India?
What is the share price of BioAtla, Inc.?
What is the 5 year returns of BioAtla, Inc.?
What are the high & low stock price of BioAtla, Inc. today?
What is the 52-week high and low of BioAtla, Inc. stock?